Doxorubicin-Induced Cardiotoxicity in Breast Cancer: Mechanistic Pathways, Pharmacogenomic Modifiers, and Translational Strategies.

Abstract excerpt

Doxorubicin, a prototypical anthracycline, remains an important component of breast cancer therapy, although its use has declined with the availability of effective non-anthracycline regimens and is increasingly restricted to selected high-risk settings. At the same time, anthracyclines continue to serve as first-line therapy for multiple malignancies, including lymphomas, leukemias, and sarcomas, sustaining the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotics, Antineoplastic
• Share to Cardiotoxicity